Publicaciones destacadas

Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer

Prat A; Guarneri V; Pascual T; Brasó-Maristany F; Sanfeliu E;

(...)

Vivancos A; Villagrasa P; Parker JS; Conte P; Perou CM .

Referencia:
Ebiomedicine 2022.
Customizing local and systemic therapies for women with early breast cancer: the st. gallen international consensus guidelines for treatment of early breast cancer 2021

H J Burstein; G Curigliano; B Thürlimann; W P Weber; P Poortmans 5;

M M Regan; H J Senn; E P Winer; M Gnant; Panelists of the St Gallen Consensus Conference.

Referencia:
Ann Oncol. 2021.
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy: ER activity in pre-menopausal HR+ breast cancer during CT

Chic N; Schettini F; Brasó-Maristany F; Sanfeliu E; Adamo B;

(...)

Muñoz M; Perou CM; Pascual T; Bellet M; Prat A .

Referencia:
Ebiomedicine 2021.
Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies

Prat A; Chaudhury A; Solovieff N; Paré L; Martinez D;

(...)

Brasó-Maristany F; Lteif A; Taran T; Babbar N; Su F .

Referencia:
Journal Of Clinical Oncology 2021.
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy

Pascual T; Fernandez-Martinez A; Tanioka M; Dieci MV; Pernas S;

(...)

Paré L; Galvan P; Carey LA; Perou CM; Prat A.

Referencia:
Clinical Cancer Research 2021.
A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer

Prat A; Tsai YH; Pascual T; Paré L; Adamo B;

(...)

Brase JC; Rodrik-Outmezguine V; Johnston S; Ciruelos E; Parker JS .

Referencia:
Clinical Cancer Research 2020.
Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial

Ciruelos E; Villagrasa P; Pascual T; Oliveira M; Pernas S;

(...)

Galván P; Canes J; Nuciforo P; Gonzalez X; Prat A .

Referencia:
Clinical Cancer Research 2020.
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

Prat A; Guarneri V; Paré L; Griguolo G; Pascual T;

(...)

Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P.

Referencia:
Lancet Oncology 2020.
Frequency and spectrum of PIK3CA somatic mutations in breast cancer

Martínez-Sáez O; Chic N; Pascual T; Adamo B; Vidal M;

(...)

Galván P; Rodríguez AB; Martinez A; Muñoz M; Prat A .

Referencia:
Breast Cancer Research 2020.
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

Brasó-Maristany F.; Griguolo G.; Pascual T.; Paré L.; Nuciforo P.;

(...)

Gomis R.R.; Villagrasa P.; Cortés J.; Ciruelos E.; Prat A..

Referencia:
Nature Communications 2020.

Publicaciones destacadas

Customizing local and systemic therapies for women with early breast cancer: the st. gallen international consensus guidelines for treatment of early breast cancer 2021